When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Câncer de bexiga

Last reviewed: 3 Jun 2025
Last updated: 17 Jan 2025

Summary

Definition

History and exam

Key diagnostic factors

  • presença de fatores de risco
  • hematúria (visível ou não visível)
Full details

Other diagnostic factors

  • polaciúria
  • disúria
Full details

Risk factors

  • exposição ao tabaco
  • exposição a carcinógenos químicos
  • idade >65 anos
  • radiação pélvica
  • uso de ciclofosfamida
  • Infecção por Schistosoma
  • sexo masculino
  • inflamação crônica da bexiga
  • predisposição genética
  • diabetes mellitus
Full details

Diagnostic tests

1st tests to order

  • urinálise
Full details

Tests to consider

  • cistoscopia
  • citologia da urina
  • urograma por tomografia computadorizada (TC)
  • urograma por ressonância magnética (RM)
  • ultrassonografia renal e vesical
  • Hemograma completo
  • perfil bioquímico (incluindo fosfatase alcalina)
  • radiografia torácica
  • TC abdominal e de pelve
  • ressonância nuclear magnética (RNM) abdominal e pélvica
  • PET-TC com fluordesoxiglucose (FDG)
  • cintilografia óssea
  • biomarcadores urinários
Full details

Treatment algorithm

ACUTE

tumores não invasivos do músculo

tumores localmente invasivos

doença metastática

Contributors

Authors

Joshua J. Meeks, MD, PhD

Associate Professor of Urology

Northwestern University Feinberg School of Medicine

Chicago

IL

გაფრთხილება:

JJM is a consultant for Merck, AstraZeneca, Incyte, Janssen, BMS, UroGen, Prokarium, Imvax, Pfizer, and Seagen/Astellas. He has received research funding from the VHA, NIH, and DoD; compensation for talks/educational courses from the AUA, OncLive, Olympus, and UroToday; and clinical trial support from SWOG, Genentech, Merck, AstraZeneca, and Incyte. JJM holds patents on T1 and TCGA classifiers; these are not currently available for use in clinical practice. JJM is an author of a reference cited in this topic.

David VanderWeele, MD, PhD

Associate Professor, Hematology and Oncology

Northwestern University Feinberg School of Medicine

Chicago

IL

გაფრთხილება:

DVW declares that he has received payments from Clovis Oncology, Exelixis, Janssen, and Bayer for advisory boards; research payments from AstraZeneca for clinical trials; payments from Astellas and Myovant for lectures; and payments from Exelixis and AstraZeneca for travel and dinner costs.

​Sarah E. Fenton, MD, PhD

Assistant Professor, Hematology and Oncology

Northwestern University Feinberg School of Medicine

Chicago

IL

გაფრთხილება:

SEF declares that she has no competing interests.

მადლიერება

Dr Joshua J. Meeks, Dr David VanderWeele, and Dr Sarah E. Fenton would like to gratefully acknowledge Dr Donald Lamm and Dr Mary Heeley, previous contributors to this topic.

გაფრთხილება:

DL is an author of a number of references cited in this topic. MH declares that she has no competing interests.

რეცენზენტები

Junaid Masood, MBBS, FRCS (Eng), MSc (Urol), FRCS (Urol)

Consultant Urological Surgeon

Homerton University Hospital NHS Foundation Trust

London

UK

გაფრთხილება:

JM declares that he has no competing interests.

Hugh Mostafid, MD

Consultant Urologist

North Hampshire Hospital

Basingstoke

UK

გაფრთხილება:

HM has received honoraria from GE Healthcare and Kyowa Kirin UK.

Thomas Guzzo, MD

Clinical Instructor of Urology

The James Buchanan Brady Urologic Institute

The Johns Hopkins Medical Institutions

Baltimore

MD

გაფრთხილება:

TG declares that he has no competing interests.

Amir Kaisary, MD, MA, ChM, FRCS

Consultant Urological Surgeon

Honorary Senior Lecturer

Department of Urology

The Royal Free & University College Medical School

London

UK

გაფრთხილება:

AK declares that he has no competing interests.

წყაროები

ჩვენი მტკიცებულებებისა და სარედაქციო ჯგუფები თანამშრომლობენ საერთაშორისო ექსპერტებსა და რეცენზენტებთან, რათა უზრუნველვყოთ თქვენი წვდომა კლინიკურად ყველაზე მნიშვნელოვან ინფორმაციაზე.

ძირითადი სტატიები

American Urological Association. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO joint guideline. 2024 [internet publication].სრული ტექსტი

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: bladder cancer [internet publication].სრული ტექსტი

European Association of Urology. Non-muscle-invasive bladder cancer. 2023 [internet publication].სრული ტექსტი

European Association of Urology. Muscle-invasive and metastatic bladder cancer. 2024 [internet publication].სრული ტექსტი

American Urological Association. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. Apr 2024 [internet publication].სრული ტექსტი

გამოყენებული სტატიები

ამ თემაში მოხსენიებული წყაროების სრული სია ხელმისაწვდომია მომხმარებლებისთვის, რომლებსაც აქვთ წვდომა BMJ Best Practice-ის ყველა ნაწილზე.

Использование этого контента попадает под действие нашего заявления об отказе от ответственности